Press Release: Moerae Matrix : Moerae Matrix Initiates Phase 1 Clinical Trial of MMI-0100, a First-in-Class Inhibitor of MK2, for Treatment of Idiopathic Pulmonary Fibrosis

MORRISTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Moerae Matrix, Inc. announced today the initiation of a Phase 1 clinical trial of MMI-0100, a first-in-class inhibitor of MAPKAP Kinase 2 (MK2) being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other...